Esperion Therapeutics Inc

Financials

Flusso di cassa derivante dalle attività operative -85.18 M-263.81 M-174.83 M-135.49 M-23.65 M-13.09 M -13.09 M Flussi di cassa derivanti dalle attività di investimento 21.36 M-50.48 M8.1 M42.5 M-317 K0 0 Liquidità derivante dalle attività di finanziamento 201.72 M268.22 M32.61 M50.46 M86.48 M36.18 M 36.18 M Liquidità libera -86.05 M-263.81 M-174.83 M-135.49 M-23.97 M-13.09 M -13.09 M

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ESPR

Financials

Esperion Therapeutics Inc

Notizie

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Esperion vende i diritti di royalty per il Giappone ad Athyrium per 50 milioni di dollari

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

BofA conferma rating Underperform su azioni Esperion Therapeutics

BofA reiterates Esperion Therapeutics stock Underperform rating

L’acido bempedoico ottiene raccomandazioni di primo livello per il colesterolo

Bempedoic acid gains top-level guideline recommendations for cholesterol

Citizens alza il target su Esperion Therapeutics per la crescita dei farmaci

Citizens raises Esperion Therapeutics price target on drug growth

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

H.C. Wainwright conferma Buy su Esperion con target di 16$

H.C. Wainwright reiterates Buy on Esperion stock, $16 target